Seattle Genetics

AstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UK After receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and the University of Oxford have resumed the trials of their experimental coronavirus candidate AZD1222 in the country. A rapid review by the tria...

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has recently signed a USD 650 million deal to acquire near-global rights to Poxel pharma’s phase 3-ready Type 2 diabetes drug (imeglimin). It’s been a while since Poxel was waiting f...

With patent loss looming, Takeda knocks proposed Velcade copycats in FDA petition Takeda’s multiple myeloma blockbuster Velcade is quickly running out of patent protection, but the drug maker has filed a citizen petition it hopes can stave off competition for a little while longer. The Japanese pharma giant asked th...

Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the d...

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the ch...